1,290 results on '"Hawkey, C."'
Search Results
52. Clinical trial: healing of NSAID-associated gastric ulcers in patients continuing NSAID therapy – a randomized study comparing ranitidine with esomeprazole
53. Novel endoscopic observation in Barrettʼs oesophagus using high resolution magnification endoscopy and narrow band imaging
54. A randomized, double-blind, placebo-controlled trial of lenalidomide in the treatment of moderately severe active Crohnʼs disease
55. Efficacy of esomeprazole for resolution of symptoms of heartburn and acid regurgitation in continuous users of non-steroidal anti-inflammatory drugs
56. Increased risk of myocardial infarction as first manifestation of ischaemic heart disease and nonselective nonsteroidal anti-inflammatory drugs
57. European evidence based consensus on the diagnosis and management of Crohn’s disease: special situations
58. Acetic acid-enhanced magnification endoscopy in the diagnosis of specialized intestinal metaplasia, dysplasia and early cancer in Barrettʼs oesophagus
59. COX-2 chronology
60. Prevalence and incidence of gastroduodenal ulcers during treatment with vascular protective doses of aspirin
61. Does concurrent prescription of selective serotonin reuptake inhibitors and non-steroidal anti-inflammatory drugs substantially increase the risk of upper gastrointestinal bleeding?
62. Gastrointestinal: Early endoscopic findings in watermelon stomach identified by the magnifying endoscopy-adaptive IHb color enhancement technique
63. Immunology
64. Effect of indomethacin and misoprostol on fasted gallbladder volume and meal-induced gallbladder contractility in humans
65. Therapeutic interventions in gastrointestinal disease based on an understanding of inflammatory mediators
66. Therapeutic Arthritis Research and Gastrointestinal Event Trial of lumiracoxib – study design and patient demographics
67. Non-steroidal anti-inflammatory drugs: who should receive prophylaxis?
68. Introduction
69. Reduced incidence of gastroduodenal ulcers associated with lumiracoxib compared with ibuprofen in patients with rheumatoid arthritis
70. An analysis of haematological findings on a feral population of aldabra giant tortoises (Geochelone gigantea)
71. The value of comparative haematological studies
72. Gastrointestinal safety of AZD3582, a cyclooxygenase inhibiting nitric oxide donator: proof of concept study in humans
73. Effect of esomeprazole on development of gastric and duodenal ulcers in high risk nsaid users
74. Relationship between abdominal symptoms and gastroduodenal ulcers and erosions in patients taking low-dose aspirin
75. Potential role for peroxisome proliferator activated receptor (PPAR) in preventing colon cancer
76. Incidence of gastroduodenal ulcers in patients with rheumatoid arthritis after 12 weeks of rofecoxib, naproxen, or placebo: a multicentre, randomised, double blind study
77. Non-steroidal anti-inflammatory drugs: overall risks and management. Complementary roles for COX-2 inhibitors and proton pump inhibitors
78. Safety and efficacy of 7-day rabeprazole- and omeprazole-based triple therapy regimens for the eradication of Helicobacter pylori in patients with documented peptic ulcer disease
79. An Irritable Bowel Syndrome-Specific Symptom Questionnaire: Development and Validation
80. NOX1 loss-of-function genetic variants in patients with inflammatory bowel disease
81. IBD risk loci are enriched in multigenic regulatory modules encompassing putative causative genes
82. Influence of sex and Helicobacter pylori on development and healing of gastroduodenal lesions in non-steroidal anti-inflammatory drug users
83. Relative contribution of mucosal injury and Helicobacter pylori in the development of gastroduodenal lesions in patients taking non-steroidal anti-inflammatory drugs
84. LETTER: Upper gastrointestinal bleeding and surrogate end points: Author's reply
85. Cyclooxygenase inhibition: between the devil and the deep blue sea
86. Interactions between Helicobacter pylori and other risk factors for peptic ulcer bleeding
87. Indigestion and non-steroidal anti-inflammatory drugs
88. Influence of risk factors on endoscopic and clinical ulcers in patients taking rofecoxib or ibuprofen in two randomized controlled trials
89. Drug treatments in upper gastrointestinal bleeding: value of endoscopic findings as surrogate end points
90. Characteristics of patients with irritable bowel syndrome recruited from three sources: implications for clinical trials
91. Review article: the gastrointestinal safety profile of rofecoxib, a highly selective inhibitor of cyclooxygenase-2, in humans
92. Comparative Mammalian Haematology : Cellular Components and Blood Coagulation of Captive Wild Animals
93. Cyclooxygenase (COX) 1 and 2 in normal, inflamed, and ulcerated human gastric mucosa
94. A lay doctorʼs guide to the inflammatory process in the gastrointestinal tract
95. Acid suppression in peptic ulcer haemorrhage: a ‘meta-analysis’
96. High prevalence of potentially virulent strains of Helicobacter pylori in the general male British population
97. Stem cell transplantation for inflammatory bowel disease: practical and ethical issues
98. Dose-dependent effects of ketoprofen on the human gastric mucosa in comparison with ibuprofen
99. Low-dose misoprostol for the prevention of low-dose aspirin-induced gastroduodenal injury
100. Reply-On dissonances, Helicobacter pylori and NSAIDs
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.